Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
03 May 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-buy-radiology-specialist-mariana-oncology-1-billion-2024-05-02/
07 Sep 2023
// BUSINESSWIRE
07 Sep 2023
// Gabrielle Masson FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/eli-lilly-hops-aboard-mariana-oncologys-175m-series-b-radiopharmaceuticals-mission
Details:
Through the acquisition Novartis expand its radiopharmaceutical pipeline and platform by including Mariana Oncology’s lead program, MC-339, a novel radioligand therapy designed to target small-cell lung cancer.
Lead Product(s): MC-339
Therapeutic Area: Oncology Brand Name: MC-339
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: $1,750.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition May 02, 2024
Lead Product(s) : MC-339
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : $1,750.0 million
Deal Type : Acquisition
Details : Through the acquisition Novartis expand its radiopharmaceutical pipeline and platform by including Mariana Oncology’s lead program, MC-339, a novel radioligand therapy designed to target small-cell lung cancer.
Brand Name : MC-339
Molecule Type : Peptide
Upfront Cash : $1,000.0 million
May 02, 2024
Details:
The proceeds will support the advancement of Mariana's novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, a peptidic small molecule engineered to carry an actinium payload for the targeted radiopharmaceutical therapy.
Lead Product(s): MC-339
Therapeutic Area: Oncology Brand Name: MC-339
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Deep Track Capital
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 07, 2023
Lead Product(s) : MC-339
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Deep Track Capital
Deal Size : $175.0 million
Deal Type : Series B Financing
Mariana Oncology Announces $175 Million Series B Financing
Details : The proceeds will support the advancement of Mariana's novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, a peptidic small molecule engineered to carry an actinium payload for the targeted radiopharma...
Brand Name : MC-339
Molecule Type : Peptide
Upfront Cash : Undisclosed
September 07, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?